Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., systemic lupus erythematosus, dermatomyositis or rheumatoid arthritis.

Abstract: The present invention relates to an inhibitor of the ROCK-PDK1 protein kinase complex for use thereof as an anti-inflammatory and anti-interferon agent. The present invention also relates to a pharmaceutical composition comprising an inhibitor of the ROCK-PDK1 protein kinase complex as active principle and at least one pharmaceutically acceptable excipient and/or carrier and/or a diluent and/or a pharmaceutically acceptable vehicle. The present invention also relates to the use of said one pharmaceutical composition in the prevention and/or the treatment of inflammatory diseases, viral and/or bacterial infections and autoimmune diseases.

Abstract: The invention relates to a CXCR4 receptor-binding compound for use for increasing or restoring interferon (IFN) level in an individual, wherein the interferon is a type-I interferon (IFN-I).

Abstract: The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they have further been found to inhibit the production of inflammatory cytokines in immune cells, which renders these compounds highly advantageous for use in therapy, particularly in the treatment or prevention of an inflammatory disorder, an autoimmune disorder, an autoinflammatory disorder, or an interferonopathy, such as, e.g., lupus erythematosus, dermatomyositis or rheumatoid arthritis.

Abstract: The present invention relates to an in vitro method for testing the cytotoxicity of a candidate compound for living target cells, said method relying on the detection of the massive release of a cytosolic luminescent enzyme in the supernatant of the cells once they have been voluntarily permeabilized. The detection of this release is rapid and reproducible. More precisely, the method of the invention comprises the steps: a) contacting, with a candidate compound, living target cells that constitutively express in their cytosol a luminescent enzyme, b) isolating the supernatant of the coculture of step a) in a second recipient, c) adding in said second recipient the substrate of said luminescent enzyme, and d) measuring the luminescence emitted in said second recipient. The cytotoxicity of said candidate compound is then proportional to the increase in luminescence measured in step d).

Abstract: The invention relates to a CXCR4 receptor-binding compound for use for increasing or restoring interferon (IFN) level in an individual, wherein the interferon is a type-I interferon (IFN-I).

Abstract: The invention relates to a CXCR4 receptor-binding compound for use for decreasing interferon (IFN) level in an individual.